WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow Infiltrating Lymphocytes (MILs®)

On October 13, 2020 WindMIL Therapeutics and Stephenson Cancer Center reported that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with renal (RCC) and urothelial carcinomas (UC) (Press release, WindMIL Therapeutics, OCT 13, 2020, View Source [SID1234568460]). The study will evaluate generating marrow infiltrating lymphocytes (MILs) for these patients through WindMIL’s proprietary cellular activation and expansion process. The study is being conducted at Stephenson Cancer Center at OU Medicine in Oklahoma City, OK.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!